Herbst: OK, next question. Let's talk about EGFR. There was a plenary talk in EGFR, the LAURA trial, and then there were a couple of studies looking at other ways to target EGFR. Let's start with the ...
Special Report: Race Oncology has taken a significant step forward in the clinical development of its next-generation cancer ...
Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn The Biologics ...
A daily pill called osimertinib (Tagrisso) is delivering far longer cancer control for adults with unresectable stage 3 EGFR-mutated non-small cell lung cancer after chemoradiation and is now ...
AstraZeneca (NASDAQ:AZN) said its drug Tagrisso has been approved by EU regulators for the treatment of EGFR-mutation non-small cell lung cancer, or NSCLC. The European Commission approved Tagrisso ...
Prestigious award supports a strong oncology workforce to create lifesaving lung cancer breakthroughsWASHINGTON, Nov. 24, 2025 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung ...
Hosted on MSN
Is Lung Cancer Hereditary?
A lung cancer diagnosis can feel frightening. And when a family member is diagnosed, you might wonder about your own risk, prompting you to ask if lung cancer is hereditary. Smoking tobacco accounts ...
Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback